Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose - The Ponderosa Project

被引：0
|
作者：
Clauss, C. [1 ]
Fabisch, C. [1 ]
Ernst, T. [1 ]
Schenk, T. [1 ]
Saussele, S. [2 ]
Tesch, H. [3 ]
Mayer, J. [4 ]
Hochhaus, A. [1 ]
机构：
[1] Univ Klinikum Jena, Klin Innere Med 2, Abt Hamatol & Internist Onkol, Jena, Germany
[2] Univ Med Mannheim, Med Klin 3, Hamatol & Internist Onkol, Mannheim, Germany
[3] Praxis Hamatol & Onkol, Frankfurt, Germany
[4] Ceska leukemicka Spolecnost Pro Zivot, Brno, Czech Republic
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P775
引用
收藏
页码：219 / 219
页数：1
相关论文
共 50 条
  • [1] Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)
    Breccia, Massimo
    Iurlo, Alessandra
    Pane, Fabrizio
    Scortechini, Anna Rita
    Attolico, Immacolata
    Santoro, Marco
    Cerrano, Marco
    Lunghi, Francesca
    Maggi, Alessandro
    Di Renzo, Nicola
    Sargentini, Valeria
    Piciocchi, Alfonso
    Tringali, Claudia
    Malato, Alessandra
    BLOOD, 2024, 144 : 2428 - 2428
  • [2] Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial
    Iurlo, Alessandra
    Annunziata, Mario
    Albano, Francesco
    Luciano, Luigia
    Spadano, Raffaele
    Scortechini, Anna Rita
    Bonifacio, Massimiliano
    Abruzzese, Elisabetta
    Lunghi, Monia
    Malato, Alessandra
    Di Renzo, Nicola
    Piciocchi, Alfonso
    Pellegrino, Angela
    Galimberti, Claudia
    Foa, Robin
    Breccia, Massimo
    BLOOD, 2019, 134
  • [3] Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial
    Breccia, Massimo
    Luciano, Luigia
    Annunziata, Mario
    Attolico, Imma
    Malato, Alessandra
    Abruzzese, Elisabetta
    Bonifacio, Massimiliano
    Scortechini, Anna Rita
    Cascavilla, Nicola
    Di Renzo, Nicola
    Impera, Stefana
    Lunghi, Monia
    Santoro, Marco
    Castagnetti, Fausto
    Maggi, Alessandro
    Sargentini, Valeria
    Piciocchi, Alfonso
    Galimberti, Claudia
    Iurlo, Alessandra
    BLOOD, 2021, 138
  • [4] Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study
    Nicolini, Franck E.
    Abruzzese, Elisabetta
    Roth-Guepin, Gabrielle
    Abi-Tayeh, Rami
    Alcazer, Vincent
    Hayette, Sandrine
    Biostat, Stephane Morisset
    Huguet, Francoise
    Iezza, Miriam
    Castagnetti, Fausto
    Rea, Delphine
    BLOOD, 2023, 142
  • [5] High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib
    Pritchard, Justin R.
    Lustgarten, Stephanie
    Hodgson, Graeme
    Baccarani, Michele
    Cortes, Jorge E.
    Deininger, Michael W.
    Guilhot, Francois
    Hochhaus, Andreas
    Hughes, Timothy P.
    Shah, Neil P.
    Talpaz, Moshe
    Clackson, Tim
    Haluska, Frank G.
    Knickerbocker, Ronald
    Rivera, Victor M.
    BLOOD, 2014, 124 (21)
  • [6] ANALYSIS OF THE RELATIONSHIP BETWEEN DOSE AND BCR-ABL HALVING TIME IN CP-CML PATIENTS TREATED WITH PONATINIB OR IMATINIB
    Pritchard, J.
    Lustgarten, S.
    Hodgson, J. G.
    Baccarani, M.
    Cortes, J. E.
    Deininger, M. W.
    Guilhot, F.
    Hughes, T. P.
    Shah, N. P.
    Talpaz, M.
    Mueller, M. C.
    Clackson, T.
    Haluska, F. G.
    Knickerbocker, R.
    Rivera, V. M.
    HAEMATOLOGICA, 2015, 100 : 448 - 449
  • [7] The OMNI patient registry: A prospective observational registry to assess vascular safety in patients with CML and Ph plus ALL treated with ponatinib.
    Stemhagen, Annette
    Adib, Deyaa
    Lustgarten, Stephanie
    McGarry, Lisa
    Du Moulin, Ruth
    Santillana, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] PONATINIB EVALUATION AND SAFETY IN REAL LIFE CHRONIC PHASE (CP) CML PATIENTS FAILING ≥2 TYROSINE KINASE INHIBITORS (TKI): UPDATE OF THE PEARL OBSERVATIONAL STUDY
    Nicolini, F. E.
    Heiblig, M.
    Caillot, D.
    Charbonnier, A.
    Rousselot, P.
    Coiteux, V.
    Escoffre-Barbe, M.
    Dubruille, V.
    Huguet, F.
    Guilhot, F.
    Hermet, E.
    Guerci-Bresler, A.
    Ame, S.
    Mouchel, P.
    Roy, L.
    Morisset, S.
    Etienne, G.
    Rea, D.
    HAEMATOLOGICA, 2016, 101 : 456 - 456
  • [9] MEGALOBLASTOID ERYTHROPOIESIS IN IMATINIB TREATED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS - DOES IT HAVE ANY SIGNIFICANCE? COULD IT BE A POSSIBLE FORERUNNER TO MYELODYSPLASIA?
    Paul, T.
    Uppin, S.
    Uppin, M.
    Tandon, A.
    Jacob, R.
    Raghunadharao, D.
    LEUKEMIA RESEARCH, 2015, 39 : S145 - S145
  • [10] Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance?
    O'Shea, D
    Crotty, G
    Carroll, P
    Conneally, E
    McCann, S
    Neat, MJ
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (03) : 367 - 369
12345